BidaskClub lowered shares of GenMark Diagnostics (NASDAQ:GNMK) from a buy rating to a hold rating in a report released on Tuesday.

A number of other equities research analysts have also recently commented on GNMK. ValuEngine raised shares of GenMark Diagnostics from a strong sell rating to a sell rating in a report on Friday, August 10th. Canaccord Genuity upped their target price on shares of GenMark Diagnostics from $9.00 to $10.00 and gave the company a buy rating in a report on Tuesday, July 31st. Needham & Company LLC reaffirmed a buy rating and issued a $11.00 target price on shares of GenMark Diagnostics in a report on Tuesday, July 31st. Finally, Zacks Investment Research cut shares of GenMark Diagnostics from a hold rating to a sell rating in a report on Wednesday, July 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. GenMark Diagnostics presently has a consensus rating of Hold and a consensus price target of $10.50.

NASDAQ GNMK opened at $7.64 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.04 and a quick ratio of 1.80. GenMark Diagnostics has a 1 year low of $3.63 and a 1 year high of $9.93. The firm has a market capitalization of $441.01 million, a price-to-earnings ratio of -6.31 and a beta of 0.88.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Monday, July 30th. The medical equipment provider reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). GenMark Diagnostics had a negative net margin of 91.58% and a negative return on equity of 87.96%. The company had revenue of $14.94 million during the quarter, compared to analyst estimates of $14.74 million. sell-side analysts anticipate that GenMark Diagnostics will post -0.85 EPS for the current fiscal year.

In other news, insider Hany Massarany sold 6,010 shares of the company’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $7.39, for a total value of $44,413.90. Following the completion of the sale, the insider now directly owns 688,694 shares of the company’s stock, valued at $5,089,448.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 20,230 shares of company stock valued at $147,242 over the last ninety days. Corporate insiders own 7.09% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Northern Trust Corp raised its holdings in shares of GenMark Diagnostics by 3.5% in the second quarter. Northern Trust Corp now owns 662,837 shares of the medical equipment provider’s stock valued at $4,229,000 after buying an additional 22,692 shares during the last quarter. Private Wealth Partners LLC raised its holdings in GenMark Diagnostics by 23.3% during the second quarter. Private Wealth Partners LLC now owns 370,000 shares of the medical equipment provider’s stock worth $2,361,000 after purchasing an additional 70,000 shares in the last quarter. Millennium Management LLC raised its holdings in GenMark Diagnostics by 1,118.6% during the second quarter. Millennium Management LLC now owns 741,752 shares of the medical equipment provider’s stock worth $4,732,000 after purchasing an additional 680,882 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in GenMark Diagnostics during the second quarter worth about $152,000. Finally, Needham Investment Management LLC raised its holdings in GenMark Diagnostics by 27.8% during the second quarter. Needham Investment Management LLC now owns 230,000 shares of the medical equipment provider’s stock worth $1,467,000 after purchasing an additional 50,000 shares in the last quarter. 99.47% of the stock is owned by institutional investors and hedge funds.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Read More: Leveraged Buyout (LBO)

Analyst Recommendations for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.